Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
about
Novel perspectives on mucormycosis: pathophysiology, presentation, and management.Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseasesRecent advances in the management of mucormycosis: from bench to bedsideMucormycosis in a renal transplant recipient: case report and comprehensive review of literatureHow to manage aspergillosis in non-neutropenic intensive care unit patientsAdvances in the treatment of invasive neonatal candidiasisPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsClinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of Americacontinuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.Cerebral phaeohyphomycosis caused by Fonsecaea monophora.Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.The role of voriconazole in the treatment of central nervous system blastomycosis.Effects of immunomodulatory and organism-associated molecules on the permeability of an in vitro blood-brain barrier model to amphotericin B and fluconazoleEfficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis.Clinical and laboratory update on blastomycosis.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Antifungal pharmacodynamics: review of the literature and clinical applications.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Recent advances in the treatment of mucormycosis.Population pharmacokinetics of amphotericin B lipid complex in neonates.Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbitsOcular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.Primary central nervous system phaeohyphomycosis: a review of 101 cases.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelHuman pharmacogenomic variations and their implications for antifungal efficacy.Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.Human Fungal Pathogens of Mucorales and Entomophthorales.Antifungal pharmacokinetics and pharmacodynamicsAnidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.Antifungal therapy and outcomes in infants with invasive Candida infections.Combination therapy for mucormycosis: why, what, and how?Liposomal amphotericin B: clinical experience and perspectives.Fungal CNS infections in patients with hematologic malignancy.Management of intracranial fungal infections in patients with haematological malignancies.Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.
P2860
Q24530554-3C4A051F-D2CB-4977-9400-5F98B7F53947Q24542404-36D4E02F-0408-45C7-BE11-4DBCC964285BQ24642450-31B9FC48-B47A-4117-B1D4-437CA4790D78Q26860727-C1CC36CA-B34D-408F-AF36-9CF4427D6EB0Q26999448-F95E59BE-718D-4BD7-9700-9871AD263054Q27022585-7A1BEE85-9E36-410C-9421-A9A82C232481Q27025299-792A6F68-AC61-4107-B7CD-1FFB07AD8EA1Q28255282-C3650729-4A35-40AD-8E49-C201031AA500Q28534551-52C5DFF7-79DF-482B-A3CB-4867F6A96851Q30274757-259922F6-FE17-41D9-895B-E79022647AA0Q31006560-798C1AAB-4A01-404D-A7A7-8981ABCC34B7Q33237758-23A9D09C-6FD1-4734-B0AD-BFE0DAE8A205Q33499168-0F363ECE-E60F-42F7-B1D9-5C57933A0239Q33676112-7D7C110F-C760-4BE3-A04E-72068ECE0C1DQ33721998-EB9E4C8D-94D8-4E56-82F1-F7D726D603D9Q33825592-5ABF27B3-C5D6-43DD-923C-65678BDA54E3Q33983506-AB0BD8D6-4594-416F-AB04-579E2FD11CF2Q33983629-19CE6781-D0B2-4822-B6B1-39C2CD532D3DQ34083129-692BD3AC-475D-4D2F-B1C3-3A390DDAB75AQ34142328-F626672D-EB14-4EDE-9FF3-7A7D2415A707Q34161213-B37CCC08-DEA8-4E17-955F-36C0EB2AEEFCQ34228332-8E9E2CA1-DE2F-4EA2-B388-CAFA387965B8Q34229980-68290F19-A8C3-4115-BEA5-BBB8F0C15BEDQ34251910-C6553C0D-E045-499F-8A05-0AE911D4B7AAQ34286912-6E113A82-5780-4BC7-89F5-46DF833F7896Q34335230-9C9279BD-4F8A-44FB-801D-EC0EB1F9AF70Q34352186-9F41A6F8-C950-4E21-A71A-4086E71A4632Q34505582-1AAFB8CC-752E-4687-B02D-FF6A8475E259Q34680675-D7897ECF-3A4C-451E-9349-57FEEE9F578BQ35070838-F81E2E0F-05F5-4053-9096-72E675F3F03EQ35091593-7E94366A-4680-4D10-8C0E-9EE600B5B67FQ35245238-D31FA6EE-128F-422B-83E0-5B2253176770Q35663841-9D0AD7D5-C261-4B68-9849-A9A9AC973008Q35689202-EED1559E-5A7F-44D9-9435-A533E4896958Q35897495-15BDEE9B-5D37-473C-9BA4-2B99BCF71531Q35974333-29BB4C58-4F9A-4D46-80B3-2FD45C28D2B9Q36140647-609945FB-BC3A-42A4-A972-0428D1DF2264Q36278069-70817B7F-D7CB-48F4-96A9-8F4C18EDA918Q36286439-E4C71F99-6C9D-490C-AA4B-C521AAFD89BCQ36422661-55AAE9F0-EB2E-4398-BAF7-20DED618CC80
P2860
Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Comparative efficacy and distr ...... of the central nervous system.
@ast
Comparative efficacy and distr ...... of the central nervous system.
@en
type
label
Comparative efficacy and distr ...... of the central nervous system.
@ast
Comparative efficacy and distr ...... of the central nervous system.
@en
prefLabel
Comparative efficacy and distr ...... of the central nervous system.
@ast
Comparative efficacy and distr ...... of the central nervous system.
@en
P2093
P356
P1476
Comparative efficacy and distr ...... of the central nervous system.
@en
P2093
Candelario M
Petraitiene R
Petraitis V
Piscitelli SC
P304
P356
10.1086/315643
P407
P577
2000-07-06T00:00:00Z